- Home
- BOLD vs MBRX Comparison
BOLD vs MBRX Comparison
Compare BOLD & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | MBRX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.2M | 23.5M |
| IPO Year | 2024 | 2016 |
Fundamental Metrics
Financial Performance| Metric | BOLD | MBRX |
|---|---|---|
| Price | $1.13 | $4.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.00 | ★ $105.50 |
| AVG Volume (30 Days) | 183.8K | ★ 309.8K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $4.36 |
| 52 Week High | $3.12 | $91.25 |
Technical Indicators
Market Signals| Indicator | BOLD | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.14 | 58.94 |
| Support Level | $1.11 | $4.75 |
| Resistance Level | $1.20 | $7.98 |
| Average True Range (ATR) | 0.07 | 0.66 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 70.00 | 57.37 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.